Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

Michael Wallington, Yong Chen, Fei Jie, Monica Patterson, Karen Repetny, Michelle Fanale, Simon Purcell, Jacob Ambrose, Christina Zettler, Andrew Belli, Laura L. Fernandes, Ching-Kun Wang

Blood (2025) 146 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2025-4511

Published: 2025

Journal Articles

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

Diego Adrianzen Herrera, Jacob Ambrose, Andrew Belli, Eric Hansen, Christina Zettler, Laura Fernandes, Ming He, Stephanie Wiley, Ching-Kun Wang

Blood (2025) 146 (Supplement 1): 4606.

https://doi.org/10.1182/blood-2025-4606

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy

Diego Adrianzen Herrera, Jacob Ambrose, Andrew Belli, Eric Hansen, Christina Zettler, Laura Fernandes, Stephanie Wiley, Courtney Anderson, Ching-Kun Wang

Blood (2025) 146 (Supplement 1): 601.

https://doi.org/10.1182/blood-2025-601

Published: 2025

Journal Articles

Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma

Benjamin Derman, Magnolia Watson, Jacob Ambrose, Christina Zettler, Andrew Belli, Laura Fernandes, Ming He

Blood (2025) 146 (Supplement 1): 2795.

https://doi.org/10.1182/blood-2025-2795

Published: 2025

Journal Articles

End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting

Paul A. Hamlin, Pallawi Torka, Eric Hansen, Andrew J. Belli, Jacob Ambrose, Christina M. Zettler, Laura L. Fernandes, Stephanie Wiley, Brittney Perry, Ching-Kun Wang

Blood (2024) 144 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2024-203786

Published: 2024

Journal Articles

Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Paul A. Hamlin, Pallawi Torka, Eric Hansen, Andrew J. Belli, Jacob Ambrose, Christina M. Zettler, Laura L. Fernandes, Stephanie Wiley, Brittney Perry, Ching-Kun Wang

Blood (2024) 144 (Supplement 1): 5101.

https://doi.org/10.1182/blood-2024-208852

Published: 2024

Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6536.

https://doi.org/10.1182/blood-2023-178727

Published: 2023

Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Blood (2023) 142 (Supplement 1): 6538.

https://doi.org/10.1182/blood-2023-180060

Published: 2023

Journal Articles

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Sharlene Dong, Ankit J. Kansagra, Gurbakhash Kaur, Anna Barcellos, Andrew J. Belli, Laura L. Fernandes, Eric Hansen, Jacob Ambrose, Claire Bai, Christina M. Zettler, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2023-180263

Published: 2023

Journal Articles

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr

Blood (2022) 140 (Supplement 1): 4142–4143.

https://doi.org/10.1182/blood-2022-170596

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy

Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma

End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting

Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only